New proton therapy may reduce side effects in esophageal cancer treatment

NCT ID NCT01512589

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two radiation methods—proton beam therapy and standard intensity-modulated radiation therapy—for people with esophageal cancer. Both are given alongside chemotherapy. The goal is to see if the newer proton therapy is safer and more effective at controlling the cancer while causing fewer side effects. About 147 adults with stage II-III esophageal cancer are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT)
What this could lead to: If proton therapy works better, it could offer a more precise radiation option for esophageal cancer with fewer side effects.
What could go wrong: This is a mid-stage trial with 147 participants, so results are not yet conclusive. Proton therapy is newer and may not prove superior to standard radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma esophageal cancer Esophageal Neoplasms squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL CANCER

Contacts and locations

Locations

MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.